Therapeutic biologics provide significant benefits to human health and address many unmet medical needs. Although several developed countries have established clear leads in biologics, China has the potential to build a world-class innovative biologics sector—if policies that support this ambition are formulated well and implemented in a timely manner.
As China aims to develop the biologics industry, three questions need to be answered: Are there lessons to be learned from the development of China’s small-molecule pharmaceutical and early-generation biologics sectors? How quickly can China catch up with leading countries in terms of breakthrough innovation? Can China’s largely unmet medical needs be translated into a meaningful market that can attract talent and economic activity and serve Chinese patients’ needs?
In a recent study commissioned by the R&D-based Pharmaceutical Association Committee in coordination with the Biotechnology Industry Organization, The Boston Consulting Group helps outline the moves China should take to aggressively position itself as a global leader in the innovative therapeutic-biologics industry.